[1]秦  超,冯永海,杨闪闪,等.结肠癌转移相关基因1表达与肺鳞状细胞癌和肺腺癌细胞顺铂耐药性的相关性[J].新乡医学院学报,2021,38(3):249-254.[doi:10.7683/xxyxyxb.2021.03.009]
 QIN Chao,FENG Yonghai,YANG Shanshan,et al.Relationship between the expression of metastasis-associated in colon cancer 1 and cisplatin resistance in pulmonary squamous cell carcinoma and pulmonary adenocarcinoma cells[J].Journal of Xinxiang Medical University,2021,38(3):249-254.[doi:10.7683/xxyxyxb.2021.03.009]
点击复制

结肠癌转移相关基因1表达与肺鳞状细胞癌和肺腺癌细胞顺铂耐药性的相关性
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年3
页码:
249-254
栏目:
临床研究
出版日期:
2021-03-05

文章信息/Info

Title:
Relationship between the expression of metastasis-associated in colon cancer 1 and cisplatin resistance in pulmonary squamous cell carcinoma and pulmonary adenocarcinoma cells
作者:
秦  超1冯永海2杨闪闪2郭 迪2
(1.郑州大学第五附属医院重症医学科,河南 郑州 410052;2.郑州大学第五附属医院呼吸与危重症医学科,河南 郑州 410052)
Author(s):
QIN Chao1FENG Yonghai2YANG Shanshan2GUO Di2
(1.Department of Critical Care Medicine,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 410052,Henan Province,China2.Department of Respiratory and Critical Care Medicine,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 410052,Henan Province,China)
关键词:
肺腺癌肺鳞状细胞癌顺铂结肠癌转移相关基因1耐药性
Keywords:
pulmonary adenocarcinomapulmonary squamous cell carcinomacisplatinmetastasis-associated in colon cancer 1drug resistance
分类号:
R73
DOI:
10.7683/xxyxyxb.2021.03.009
文献标志码:
A
摘要:
目的 探讨结肠癌转移相关基因1(MACC1)与肺鳞状细胞癌和肺腺癌细胞顺铂耐药性的关系。方法 收集2018年1月至2019年12月郑州大学第五附属医院手术切除的新鲜肺腺癌组织标本37例和肺鳞状细胞癌组织标本23例,所有患者术前未行放射治疗和化学治疗。取新鲜癌组织行原代细胞体外培养。取第2代肺鳞状细胞癌和肺腺癌细胞,将癌细胞分别均分为顺铂组和对照组,顺铂组细胞以含顺铂的培养液继续培养72 h,对照组细胞按原代细胞培养液继续培养72 h,采用甲基噻唑基四唑(MTT)法检测肺鳞状细胞癌和肺腺癌细胞对顺铂的敏感性。取新鲜癌组织,采用免疫组织化学染色检测肺腺癌和肺鳞状细胞癌组织中MACC1蛋白的表达。取第2代肺鳞状细胞癌和肺腺癌细胞,反转录-聚合酶链反应法检测肺腺癌和肺鳞状细胞癌细胞中MACC1 mRNA的表达。结果 37例肺腺癌患者对顺铂的敏感率为59.46%(22/37),耐药率为40.54%(15/37);23例肺鳞状细胞癌患者对顺铂的敏感率为52.17%(12/23),耐药率为47.83%(11/23);肺腺癌与肺鳞状细胞癌患者对顺铂的敏感性比较差异无统计学意义(χ2=2.849,P>0.05)。高、中、低分化肺腺癌对顺铂的耐药率分别为41.67%(5/12)、42.11%(8/19)、33.33%(2/6),高、中、低分化肺腺癌对顺铂的耐药率比较差异无统计学意义(χ2=2.916,P>0.05),高、中、低分化肺鳞状细胞癌对顺铂的耐药率分别为50.00%(2/4)、46.67%(7/15)、50.00%(2/4),高、中、低分化肺鳞状细胞癌对顺铂的耐药率比较差异无统计学意义(χ2=1.527,P>0.05);高、中、低分化的肺腺癌与肺鳞状细胞癌对顺铂的耐药率比较差异均无统计学意义(χ2=2.014、1.034、1.679,P>0.05)。Ⅰ、Ⅱ、Ⅲa、Ⅲb、Ⅳ期肺腺癌对顺铂的耐药率分别为0.00%(0/2)、33.33%(1/3)、36.36%(4/11)、38.46%(5/13)、62.50%(5/8);随着TNM分期升高,肺腺癌对顺铂的耐药率升高(χ2=21.417,P<0.05)。Ⅰ、Ⅱ、Ⅲa、Ⅲb、Ⅳ期肺鳞状细胞癌对顺铂的耐药率分别为0.00%(0/1)、33.33%(1/3)、44.44%(4/9)、50.00%(4/8)、100.00%(2/2);随着TNM分期升高,肺鳞状细胞癌对顺铂的耐药率升高(χ2=19.034,P<0.05)。Ⅰ、Ⅱ、Ⅲa期肺腺癌与肺鳞状细胞癌对顺铂的耐药率比较差异无统计学意义(χ2=2.327、0.159、0.827,P>0.05);Ⅲb、Ⅳ期肺腺癌对顺铂的耐药率显著低于肺鳞状细胞癌(χ2=8.361、10.357,P<0.05)。肺腺癌和肺鳞状细胞癌组织中MACC1蛋白表达比较差异无统计学意义(χ2=3.119,P>0.05)。肺腺癌和肺鳞状细胞癌细胞中MACC1 mRNA相对表达量分别为1.217±0.012、1.137±0.011,肺腺癌与肺鳞状细胞癌细胞中MACC1 mRNA相对表达量比较差异无统计学意义(t=12.137,P>0.05)。肺腺癌和肺鳞状细胞癌组织中MACC1蛋白表达与顺铂耐药性呈正相关(r= 0.747、0.681,P<0.05)。结论 肺腺癌和肺鳞状细胞癌对顺铂的耐药率较高,肺腺癌和肺鳞状细胞癌组织中MACC1蛋白表达与顺铂耐药性呈正相关,MACC1可能参与了肺腺癌和肺鳞状细胞癌对顺铂耐药的发生机制。
Abstract:
Objective To investigate the relationship between the expression of metastasis-associated in colon cancer 1 (MACC1) and cisplatin resistance in pulmonary squamous cell carcinoma and pulmonary adenocarcinoma cells.Methods  The fresh cancer tissue specimens of 37 cases of pulmonary adenocarcinoma and 23 cases of pulmonary squamous cell carcinoma were collected in the Fifth Affiliated Hospital of Zhengzhou University from January 2018 to December 2019.All patients did not receive radiotherapy and chemotherapy before operation.The fresh cancer tissues were taken for primary cell culture in vitro.The second generation cancer cells of pulmonary squamous cell carcinoma and pulmonary adenocarcinoma were collected and divided into cisplatin group and control group.The cells in the cisplatin group were cultured in medium containing cisplatin for 72 hours,while the cells in the control group were cultured in primary culture medium for 72 hours.The sensitivity of pulmonary squamous cell carcinoma and pulmonary adenocarcinoma cells to cisplatin was detected by methyl thiazolyl tetrazolium (MTT) method.The fresh cancer tissues was obtained,and the expression of MACC1 protein in pulmonary squamous cell carcinoma and pulmonary adenocarcinoma tissues was detected by immunohistochemistry.The second generation cancer cells of pulmonary squamous cell carcinoma and pulmonary adenocarcinoma were collected,and the expression of MACC1 mRNA in pulmonary squamous cell carcinoma and pulmonary adenocarcinoma cells was detected by reverse transcription-polymerase chain reaction.Results The sensitivity rate of 37 cases of pulmonary adenocarcinoma to cisplatin was 59.46% (22/37),and the drug resistance rate was 40.54% (15/37).The sensitivity rate of 23 cases of pulmonary squamous cell carcinoma to cisplatin was 52.17% (12/23),and the drug resistance rate was 47.83% (11/23).There was no significant difference in the sensitivity of pulmonary adenocarcinoma and pulmonary squamous cell carcinoma to cisplatin (χ2=2.849,P>0.05).The resistance rate of highly,moderately and poorly differentiated pulmonary adenocarcinoma to cisplatin was 41.67% (5/12),42.11% (8/19) and 33.33% (2/6),respectively.There was no significant difference in the resistance rate of highly,moderately and poorly differentiated pulmonary adenocarcinoma to cisplatin (χ2=2.916,P>0.05).The resistance rate of highly,moderately and poorly differentiated pulmonary squamous cell carcinoma to cisplatin was 50.00% (2/4),46.67% (7/15) and 50.00% (2/4),respectively.There was no significant difference in the resistance rate of highly,moderately and poorly differentiated pulmonary squamous cell carcinoma to cisplatin (χ2=1.527,P>0.05).There was no significant difference in cisplatin resistance rate between the highly,moderately and poorly differentiated pulmonary adenocarcinoma and pulmonary squamous cell carcinoma (χ2=2.014,1.034,1.679;P>0.05).The resistance rate of pulmonary adenocarcinoma of stage Ⅰ,Ⅱ,Ⅲa,Ⅲb and Ⅳ to cisplatin was 0.00% (0/2),33.33% (1/3),36.36% (4/11),38.46% (5/13) and 62.50% (5/8),respectively.With the increase of TNM stage,the resistance rate of pulmonary adenocarcinoma to cisplatin was higher (χ2=21.417,P<0.05).The resistance rate of pulmonary squamous cell carcinoma of stage Ⅰ,Ⅱ,Ⅲa,Ⅲb and Ⅳ to cisplatin was 0.00% (0/1),33.33% (1/3),44.44% (4/9),50.00% (4/8) and 100.00% (2/2),respectively.With the increase of TNM stage,the resistance rate of pulmonary squamous cell carcinoma to cisplatin was higher (χ2=19.034,P<0.05).There was no significant difference in cisplatin resistance rate between the pulmonary adenocarcinoma and pulmonary squamous cell carcinoma of stage Ⅰ,Ⅱ,Ⅲa (χ2=2.327,0.159,0.827;P>0.05).The cisplatin resistance rate of pulmonary adenocarcinoma of stage Ⅲb and Ⅳ was significantly lower than that of pulmonary squamous cell carcinoma (χ2=8.361,10.357;P<0.05).There was no significant difference in the expression of MACC1 protein between pulmonary adenocarcinoma and pulmonary squamous cell carcinoma (χ2=3.119,P>0.05).The relative expression of MACC1 mRNA in pulmonary adenocarcinoma and pulmonary squamous cell carcinoma cells was 1.217±0.012 and 1.137±0.011,respectively.There was no significant difference in the relative expression of MACC1 mRNA between pulmonary adenocarcinoma and pulmonary squamous cell carcinoma cells (t=12.137,P>0.05).The expression of MACC1 protein in pulmonary adenocarcinoma and pulmonary squamous cell carcinoma was positively correlated with cisplatin resistance (r=0.747,0.681;P<0.05).Conclusion The resistance rate of pulmonary adenocarcinoma and pulmonary squamous cell carcinoma to cisplatin is higher.The expression of MACC1 protein in pulmonary adenocarcinoma and pulmonary squamous cell carcinoma is positively correlated with cisplatin resistance.MACC1 may be involved in the resistance mechanism of pulmonary adenocarcinoma and pulmonary squamous cell carcinoma to cisplatin.

参考文献/References:

[1] 江俊伟,葛林虎.MACC1、c-Met 蛋白与非小细胞肺癌的分化、浸润、转移及生存期的关系分析[J].实用医学杂志,2014,30(12):1936-1938.
[2] 张园.晚期非小细胞肺癌患者EGFR-TKIs及铂类药物疗效预测因素探索分析及相关耐药机制研究[D].乌鲁木齐:新疆医科大学,2018.
[3] 方亚妮.miRNA与非小细胞肺癌顺铂耐药的研究进展[J].世界最新医学信息文摘,2019,19(50):123-124.
[4] 郝兰香,潘超,唐志腾,等.核因子-κB对肝癌细胞多药耐药性的影响[J].新乡医学院学报,2020,37(10):916-920.
[5] 冯永海.抑制MACC1的表达增强非小细胞肺癌A549细胞对顺铂化学治疗的敏感性[D].郑州:郑州大学,2018.
[6] TONG G,CHENG B,LI J,et al.MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells[J].Cancer Med,2019,8(16):7044-7054.
[7] BUDCZIES J,KLUCK K,WALTHER W,et al.Decoding and targeting the molecular basis of MACC1-driven metastatic spread: lessons from big data mining and clinical-experimental approaches[J].Semin Cancer Biol,2020,60:365-379.
[8] 武世伍,王一超,慈红非,等.血管生成抑制蛋白1和结肠癌转移相关蛋白-1在肺鳞状细胞癌中的表达及其临床意义[J].南方医科大学学报,2017,37(7):952-956.
[9] 陈婧华,陈垦,陈碧君,等.MACC1和VGEFR2蛋白在晚期肺癌中的表达及其临床意义[J].广东药学院学报,2017,33(1):131-135.
[10] 张秀梅,顾金松,刘曙.肝细胞癌中MACC1基因的表达及其临床意义[J].长江大学学报(自科版):医学卷,2013,10(9):10-12.
[11] ZHANG Y M,WU Q M,CHANG L Y,et al.miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway [J].Neoplasma,2020,67(5):1042-1053.
[12] HUA F F,LIU S S,ZHU L H,et al.MiRNA-338-3p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway[J].Eur Rev Med Pharmacol Sci,2017,21(23):5342-5352.
[13] RADHAKRISHNAN H,ILM K,WALTHER W,et al.MACC1 regulates Fas mediated apoptosis through STAT1/3-Mcl-1 signaling in solid cancers[J].Cancer Lett,2017,403:231-245.

相似文献/References:

[1]贾 瑞,薛 雷,杜海荣,等.冀东满族肺腺癌患者表皮生长因子受体基因突变分析[J].新乡医学院学报,2015,32(05):408.
[2]杨艳荣.培美曲塞与吉西他滨联合顺铂治疗晚期肺腺癌疗效及安全性比较[J].新乡医学院学报,2015,32(12):1103.
[3]张建东,贺利民,马 磊,等.表皮生长因子受体基因突变和切除修复交叉互补蛋白1蛋白表达与肺腺癌患者临床病理特征及预后的关系[J].新乡医学院学报,2016,33(10):894.[doi:10.7683/xxyxyxb.2016.10.015]
 ZHANG Jian-dong,HE Li-min,MA Lei,et al.Relation of expression of epidermal growth factor receptor genic mutation&excision repair cross complementing protein1 with clinicopathological features&prognosis in pulmonary adenocarcinoma patients[J].Journal of Xinxiang Medical University,2016,33(3):894.[doi:10.7683/xxyxyxb.2016.10.015]
[4]杨成轩,贾 良,孙艳霞,等.共刺激因子B7同源体4在肺腺癌组织中的表达及临床意义[J].新乡医学院学报,2019,36(9):833.[doi:10.7683/xxyxyxb.2019.09.007]
 YANG Cheng-xuan,JIA Liang,SUN Yan-xia,et al.Expression of costimulate molecules B7 homolog 4 in lung adenocarcinoma tissues and its clinical significance[J].Journal of Xinxiang Medical University,2019,36(3):833.[doi:10.7683/xxyxyxb.2019.09.007]
[5]李晓亮,杨志刚,马希涛,等.中分化肺腺癌及癌旁组织中差异蛋白质组学分析[J].新乡医学院学报,2019,36(4):315.[doi:10.7683/xxyxyxb.2019.04.004]
 LI Xiao-liang,YANG Zhi-gang,MA Xi-tao,et al.Differential proteomic analysis of human moderately differentiated lung adenocarcinoma and adjacent tissues[J].Journal of Xinxiang Medical University,2019,36(3):315.[doi:10.7683/xxyxyxb.2019.04.004]
[6]刘 勇,徐天娇,霍金莲.Ku70乙酰化在硒诱导人肺腺癌A549细胞凋亡中的作用[J].新乡医学院学报,2017,34(2):099.[doi:10.7683/xxyxyxb.2017.02.005]
 LIU Yong,XU Tian-jiao,HUO Jin-lian.Effect of Ku70 acetylation on selenium-induced apoptosis of human pulmonary adenocarcinoma A549 cell[J].Journal of Xinxiang Medical University,2017,34(3):099.[doi:10.7683/xxyxyxb.2017.02.005]
[7]赵隽,温松,于法明,等.含Sushi重复蛋白X连锁2基因敲除对肺腺癌A549细胞生物学特性的影响[J].新乡医学院学报,2022,39(10):901.[doi:10.7683/xxyxyxb.2022.10.001]
 ZHAO Jun,WEN Song,YU Faming,et al.Effect of Sushi repeat containing protein,X-linked 2 gene knockout on the biological characteristics of lung adenocarcinoma A549 cells[J].Journal of Xinxiang Medical University,2022,39(3):901.[doi:10.7683/xxyxyxb.2022.10.001]
[8]王安生,王祖义,郑传明,等.转化生长因子β调节子4对人肺鳞状细胞癌类器官增殖、侵袭和转移的影响[J].新乡医学院学报,2022,39(10):907.[doi:10.7683/xxyxyxb.2022.10.002]
 WANG Ansheng,WANG Zuyi,ZHENG Chuanming,et al.Effect of transforming growth factor β regulator 4 on proliferation,invasion and metastasis of human lung squamous cell carcinoma organoids[J].Journal of Xinxiang Medical University,2022,39(3):907.[doi:10.7683/xxyxyxb.2022.10.002]
[9]王梦丽,韩利红,麻佑锋,等.肿瘤相关成纤维细胞外泌体对肺腺癌细胞增殖、迁移、侵袭的影响及机制[J].新乡医学院学报,2023,40(11):1016.[doi:10.7683/xxyxyxb.2023.11.003]
 WANG Mengli,HAN Lihong,MA Youfeng,et al.Effect and mechanism of cancer-associated fibroblasts exosomes on proliferation,migration and invasion of lung adenocarcinoma cells[J].Journal of Xinxiang Medical University,2023,40(3):1016.[doi:10.7683/xxyxyxb.2023.11.003]

更新日期/Last Update: 2021-03-05